A review discusses evidence based on β-secretase (BACE) hemizygous null animals and in vivo studies with prototype BACE inhibitors that low-to-moderate level of inhibition of BACE, if maintained chronically in individuals at risk for developing Alzheimer's disease (AD), may be sufficient to stave off the onset of AD until late in the normal human life expectancy curve.